December 11th, 2pm – 3:30 PM CET
This webinar updated EFPIA members on Medicines Adaptive Pathways to Patients (MAPPs) and its potential impact on research, development, licensing, HTA, and pricing & reimbursement in relation to early patient access mechanisms.
Featuring: (in order of appearance)
The topics of discussion are:
- Medicines Adaptive Pathways to Patients, their benefits for companies, patients, regulators and payers
- Opportunities and barriers to implementing MAPPs
- The status of activities which implement or support implementation of MAPPs (EMA, HTA bodies, Innovative Medicines Initiatives, Newdigs, etc)
|Programme: 90 Minutes
|What are MAPPs?
|Initiatives supporting adaptive licensing and access
Overview of EMA Pilot and NewDigs
Karin Van Baelen
Overview of the US initiative Breakthrough Designation
|Collaborative initiatives to progress and enable MAPPs implementation
Overview of IMI2 activities and plans
|Q&A until End